Open Access<p>Osteopontin Mediates Cetuximab Resistance via the MAPK Pathway in NSCLC Cells</p>
Author(s) -
Jian Cui,
Jun Wang,
Chao Lin,
Jixiang Liu,
Wei Zuo
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s228437
Subject(s) - osteopontin , cancer research , mapk/erk pathway , cetuximab , lung cancer , downregulation and upregulation , cell growth , medicine , signal transduction , cancer , biology , oncology , immunology , microbiology and biotechnology , colorectal cancer , gene , biochemistry , genetics
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The high expression of osteopontin (OPN) is an important factor that aggravates drug resistance and causes a poor prognosis in this disease. Therefore, understanding the molecular mechanism of OPN is critical for the treatment and prognosis of NSCLC.